Johnson & Johnson Reports P-IIIb (APEX) Trial Findings of Tremfya for Active Psoriatic Arthritis
Shots:
- J&J has reported P-IIIb (APEX) trial data assessing Tremfya vs PBO in biologic-naïve PsA pts with inadequate response to standard therapies for 24wks., followed by a 12wk. safety follow-up; eligible pts could enter a 2yr. extension phase prior to the final safety follow-up
- Trial met its 1EP of improved ACR20 response, showing reduced signs & symptoms as well as its 2EP of less structural damage progression per PsA-modified vdH-S score, incl. joint space narrowing & erosion at 24wks.; data to be highlighted in future conferences
- APEX trial will continue to evaluate the sustained efficacy of Tremfya in inhibiting structural damage in pts with active PsA
Ref: J&J | Image: J&J
Related News:- J&J MedTech Reports the US FDA‘s 510(k) Clearance of MONARCH QUEST for Robot-Assisted Bronchoscopy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
